Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer IncidenceBiagio Barone, Gian Maria Busetto, Alessandro Sciarra et al.|Journal of Personalized Medicine|2023Cited by 56
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched AnalysisFrancesco Del Giudice, Gian Maria Busetto, Rocco Simone Flammia et al.|Cancers|2022Cited by 17
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?Gian Maria Busetto, Luigi Cormio, Marco Finati et al.|World Journal of Urology|2023Cited by 7